$72.86
+0.05%Oct 8, 2026, 10:30 UTC
Atrium Therapeutics entered into a securities purchase agreement with institutional investors for a private placement expected to generate approximately $50 million in gross proceeds.
Source:Jun 23, 2026, 19:51 UTC
Novartis AG reported that its experimental drug del-brax, acquired through the Avidity Biosciences deal, showed promise in an early to mid-stage study for facioscapulohumeral muscular dystrophy.
Source:Jun 11, 2026, 21:41 UTC
Novartis acquired Avidity as part of a $12 billion takeover.
Source: